secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0000950170-23-032449
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio appoints Katie Peng to Board; commercial launch experience from Denali, Genentech
--------------------------------------------------------------------------------

- Katie Peng appointed to Board effective July 10, 2023; board size expanded from 8 to 9 directors.
- Ms. Peng received option to purchase 70,200 shares at $3.38/share, vesting over 36 months.
- She serves as Chief Commercial Officer at Denali Therapeutics, previously SVP at Genentech.
- Led launches of OCREVUS (MS), Evrysdi (SMA), and HEMLIBRA (hemophilia A).
- Appointment adds commercial expertise as Adicet advances ADI-001 towards pivotal study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/0000950170-23-032449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/acet-20230710.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-032449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer